ClinicalTrials.gg
Not yet recruitingNCT07790055Updated Sep 1, 2026

The Effect of Mindfulness in Inflammation Markers (IL-6, TNF-A, CRP and Cortisol) Among Survivors of Tidal Flooding in Sayung Demak

An interventional study of Mindfulness Body Scan Training in Psychological Stress, Depression - Major Depressive Disorder and Anxiety, sponsored by Natalia Dewi Wardani, MD. Not yet recruiting at 1 site in Indonesia. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-09-01.

Sponsored by Natalia Dewi Wardani, MD · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
75
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Study summary

Recurrent tidal flooding (rob) in the coastal areas of Sayung District, Demak Regency, poses a continuous environmental threat that inflicts housing damage, economic instability, and prolonged socioeconomic uncertainty on local residents. These chronic stressors frequently trigger significant psychological distress, including elevated levels of stress, anxiety, and depression, while simultaneously activating systemic inflammatory pathways and dysregulating the hypothalamic-pituitary-adrenal (HPA) axis.

Mindfulness body scan is a structured, non-pharmacological mind-body technique that involves directing non-judgmental attention to physical sensations across the body. Within a psycho-neuro-immunological framework, mindfulness practice is hypothesized to reduce physiological stress responses, promote autonomic nervous system balance, and downregulate pro-inflammatory pathways.

This randomized controlled trial evaluates the effectiveness of a structured 8-day mindfulness body scan intervention on both biological inflammatory markers and psychological outcomes among tidal flood survivors. Participants recruited from Sayung 1 Primary Health Center will be randomly allocated into two groups:

  1. Intervention Group: Receives structured 8-day Mindfulness Body Scan training.
  2. Control Group: Receives standard health monitoring. All participants will undergo baseline and post-intervention assessments, which include venous blood sampling to analyze key inflammatory and stress biomarkers-Interleukin-6 (IL-6), Tumor Necrosis Factor-alpha (TNF-α), C-Reactive Protein (CRP), and Cortisol. In addition, psychometric instruments will evaluate changes in depression, anxiety, stress, sleep quality, and overall quality of life. The primary objective is to determine whether a short-term mindfulness body scan practice can effectively reduce systemic inflammation and improve post-disaster psychological well-being in coastal communities.
Read the detailed description

Background: Recurrent tidal flooding in coastal Sayung, Demak, exposes residents to chronic environmental and socioeconomic stress, contributing to psychological distress and elevated systemic inflammation. Within a psychoneuroimmunological framework, mindfulness practices-specifically the body scan technique-may suppress pro-inflammatory pathways and regulate the hypothalamic-pituitary-adrenal (HPA) axis.

Study Design: This is a randomized controlled trial conducted at Sayung 1 Primary Health Center, Demak. Eligible adult survivors of tidal flooding will be randomly allocated to either the intervention group or the control group.

Intervention \& Control:

  • Intervention Group: Receives structured 8-day Mindfulness Body Scan training.
  • Control Group: Receives standard health monitoring.

Assessments: Baseline and 1-week post-intervention evaluations will be conducted for all participants:

  1. Biomarkers: Venous blood samples to analyze Interleukin-6 (IL-6), Tumor Necrosis Factor-alpha (TNF-α), C-Reactive Protein (CRP), and Cortisol.
  2. Psychometric Assessments: Standardized questionnaires evaluating depression, anxiety, stress, sleep quality, and quality of life.
02

Conditions studied

  • Psychological Stress
  • Depression - Major Depressive Disorder
  • Anxiety
  • Inflammation
  • Disaster

Keywords

  • psychological stress
  • anxiety
  • mindfulness
  • tidal flooding
  • depression
03

In context

Stress, Psychological

844 studies on the registry are indexed under Stress, Psychological; 136 are open to participants now.

This study's planned enrollment of 75 is below the median of 84 across 688 interventional studies indexed under Stress, Psychological.

Browse Stress, Psychological studies →

Lead sponsor

Natalia Dewi Wardani, MD is the lead sponsor of 4 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18 years or older.
  • Resident of Sayung District, Demak Regency, affected by tidal flooding (rob).
  • Registered patient at Sayung 1 Primary Health Center.
  • Capable of providing written and participating in the intervention sessions.

Exclusion criteria

Exclusion Criteria:

  • Severe cognitive impairment, active psychosis, or severe psychiatric conditions preventing participation.
  • Uncontrolled systemic or inflammatory diseases.
  • Current use of long-term systemic or therapy.
  • Inability to complete questionnaires or follow basic mindfulness instructions.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
75 participants (estimated)

Study arms

  • Experimental
    Mindfulness Body Scan

    Participants undergo structured Mindfulness Body Scan training over an 8-day period alongside standard care

    Behavioral: Mindfulness Body Scan Training

  • No intervention
    Control Group

    Participants receive standard health monitoring without the mindfulness body scan intervention

Interventions

  • BehavioralMindfulness Body Scan Training

    A structured 8-day mind-body exercise where participants systematically direct non-judgmental attention to physical sensations throughout the body from head to toe

06

What researchers measure

Primary outcomes

  1. Change in Serum Interleukin-6 (IL-6) Levels

    Measured from venous blood samples using ELISA to evaluate changes in pro-inflammatory cytokine levels (concentrations reported in pg/mL).

    Time frame: Baseline (Day 0) and post-intervention (Day 8)

  2. Change in Serum Tumor Necrosis Factor-alpha (TNF-α) Levels

    Measured from venous blood samples using ELISA to assess systemic inflammatory responses (concentrations reported in pg/mL)

    Time frame: Baseline (Day 0) and post-intervention (Day 8)

  3. Change in Serum C-Reactive Protein (CRP) Levels

    Evaluated via laboratory blood analysis as an indicator of acute phase systemic inflammation (concentrations reported in mg/L).

    Time frame: Baseline (Day 0) and post-intervention (Day 8)

  4. Change in Serum Cortisol Levels

    Measured via venous blood samples to assess HPA axis regulation and physiological stress response (concentrations reported in micro-g/dL).

    Time frame: Baseline (Day 0) and post-intervention (Day 8)

Secondary outcomes

  1. Change in Depression Score

    Measured using the Patient Health Questionnaire-9 (PHQ-9). Scores range from 0 to 27, where higher scores indicate greater severity of depression.

    Time frame: Baseline (Day 0) and post-intervention (Day 8)

  2. Change in Anxiety Score

    Measured using the Generalized Anxiety Disorder 7-item scale (GAD-7). Scores range from 0 to 21, where higher scores indicate greater severity of anxiety.

    Time frame: Baseline (Day 0) and post-intervention (Day 8)

  3. Change in Stress Score

    Measured using the Perceived Stress Scale (PSS-10). Scores range from 0 to 40, where higher scores indicate higher levels of perceived stress.

    Time frame: Baseline (Day 0) and post-intervention (Day 8)

  4. Change in Sleep Quality Score

    Measured using the Pittsburgh Sleep Quality Index (PSQI). Global scores range from 0 to 21, where higher scores indicate worse sleep quality.

    Time frame: Baseline (Day 0) and post-intervention (Day 8)

  5. Change in Quality of Life Score

    Measured using the 36-Item Short Form Health Survey (SF-36) Physical Component Summary. Scores range from 0 to 100, where higher scores represent better health-related quality of life.

    Time frame: Baseline (Day 0) and post-intervention (Day 8)

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No — The data are not publicly available due to privacy or ethical restrictions. The dataset involves sensitive information about mental health, and sharing it publicly would compromise participant confidentiality as per the ethical approval obtained.

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Sep 1, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07790055
Lead sponsor
Natalia Dewi Wardani, MD
Responsible party
Natalia Dewi Wardani, MD (Head of Psychiatry Residency Program Medical Faculty Diponegoro University, Principal Investigator, Universitas Diponegoro) — Sponsor-investigator
First posted
Aug 27, 2026
Start date
Sep 1, 2026 (estimated)
Primary completion
Feb 1, 2027 (estimated)
Completion
Apr 1, 2027 (estimated)
Last update
Sep 1, 2026

Study contacts

Natalia Dewi Wardani Dr. dr. Sp.KJ(K)
Contact
anatdew@gmail.com
+6281325683134

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion